Advanced Search

Journal of Traditional Chinese Medicine >

2023 , Vol. 43 >Issue 5: 1010 - 1018

DOI: https://doi.org/10.19852/j.cnki.jtcm.20230713.002

Clinical efficacy of Buzhong Yiqi decoction (补中益气汤) in the treatment of hospital-acquired pneumonia with multi-drug resistant bacteria: a prospective, randomized, multicenter controlled trial

  • Xiangru XU ,
  • Yi ZHOU ,
  • Gang CHEN ,
  • Ming LEI ,
  • Wen ZHANG ,
  • Xinxin WU ,
  • Yuting PU ,
  • Caiyu CHEN ,
  • Yuting SUN ,
  • Shuang ZHOU ,
  • Bangjiang FANG
Expand
  • 1 Department of Emergency, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China
    2 School of Basic Medical Sciences, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
    3 Department of Intensive Care Medicine, Seventh People’s Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai 200137, China
    4 Acupuncture and Massage College, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
    5 Institute of Critical Care, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China

Received date: 2022-12-12

  Accepted date: 2023-02-04

  Online published: 2023-07-13

Supported by

Basic Research Program of Shanghai Municipal Science and Technology Commission: A Multicenter, Randomized, Controlled Clinical Study on Fuzheng Quxie Jing Prescription "Buzhong Yiqi Decoction" in the Treatment of Hospital-acquired Pneumonia caused by Multi-drug Resistant Bacteria(18401971600);Three-year Action Plan for the Development of Traditional Chinese Medicine in Shanghai: National TCM Emergency Medical Rescue Base Construction(ZY(2021-2023)-0101-01);East China Area and Municipal TCM Specialty Disease Alliance Construction(ZY(2021-2023)-0302)

Fold

Abstract

OBJECTIVE: To evaluate the efficacy and safety of Buzhong Yiqi decoction (补中益气汤, BZYQ) in the treatment of hospital-acquired pneumonia (HAP) with multi-drug-resistant bacteria (MDRB).
METHODS: This 28-day study was conducted at 5 clinical centers in Shanghai. The eligible patients were randomly assigned (1:1) into the intervention group (BZYQ plus conventional Western Medicine therapy) and control group (conventional Western Medicine therapy). The primary outcomes were the clinical response, clinical pulmonary infection score (CPIS), and microbiologic response. The secondary outcomes were the 28-day all-cause mortality (ACM), Acute Physiology and Chronic Health Evaluation Ⅱ (APACHE Ⅱ) score, ventilator weaning rate, length of mechanical ventilation (MV), length of hospital stay, and changes of infection indicators.
RESULTS: Altogether 83 subjects in the intervention group and 85 subjects in the control group were analyzed. The clinical success rate (48.2%) and the pathogen eradication rate (59.0%) of the intervention group were all better than those of the control group (32.9% and 38.9%, respectively) with statistically significant differences (P<0.05). The CPIS score of the intervention group (8.9 ± 1.7) was lower than that of the control group (9.6 ± 2.5) (P<0.05). The length of MV in the intervention group [(13.7 ± 6.4) d] was significantly shorter than that of the control group [ (17.2 ± 7.2) d] (P<0.05). The 28-day ACM of the intervention group (13.33%) was lower than that of the control group (21.2%) with no statistically significant difference (P>0.05). The differences between two groups in ventilator weaning rate, length of hospital stay, and APACHE Ⅱ score were not statistically significant (P > 0.05). The intervention group displayed decreases in white blood cell count, C-reactive protein, neutrophil percentage, and procalcitonin at day 28 compared with baseline (P<0.05). No serious adverse events occurred in either group during the 28-day follow-up.
CONCLUSION: BZYQ may be an effective therapeutic option for the management of HAP with MDRB.

Key words： healthcare-associated pneumonia; drug resistance, multiple; bacteria; Buzhong Yiqi decoction; randomized controlled trial

Cite this article

Xiangru XU , Yi ZHOU , Gang CHEN , Ming LEI , Wen ZHANG , Xinxin WU , Yuting PU , Caiyu CHEN , Yuting SUN , Shuang ZHOU , Bangjiang FANG . Clinical efficacy of Buzhong Yiqi decoction (补中益气汤) in the treatment of hospital-acquired pneumonia with multi-drug resistant bacteria: a prospective, randomized, multicenter controlled trial[J]. Journal of Traditional Chinese Medicine, 2023 , 43(5) : 1010 -1018 . DOI: 10.19852/j.cnki.jtcm.20230713.002

References

1. Torres A, Niederman MS, Chastre J, et al. International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: Guidelines for the management of hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociación Latinoamericana del Tórax (ALAT). Eur Respir J 2017; 50: 1700582.
2. Scott RD, Culler SD, Rask KJ. Understanding the economic impact of health care-associated infections: a cost perspective analysis. J Infus Nurs 2019; 42: 61-9.
3. Cilloniz C, Dominedo C, Torres A. An overview of guidelines for the management of hospital-acquired and ventilator-associated pneumonia caused by multidrug-resistant Gram-negative bacteria. Curr Opin Infect Dis 2019; 32: 656-62.
4. Centers for Disease Control and Prevention. Antimicrobial Resistance. 2022-10-05, cited 2023-01-20. Available from URL: https://www.cdc.gov/drugresistance/about.html.
5. China Antimicrobial Resistence Surveillance System. National Bacterial Resistance Surveillance Report. 2020-11-19, cited 2022-05-14. Available from URL: http://www.carss.cn/Report/Details/770.
6. Lakbar I, Medam S, Ronflé R, et al. Association between mortality and highly antimicrobial-resistant bacteria in intensive care unit-acquired pneumonia. Sci Rep 2021; 11: 16497.
7. Paramythiotou E, Routsi C. Association between infections caused by multidrug-resistant gram-negative bacteria and mortality in critically ill patients. World J Crit Care Med 2016; 5: 111-20.
8. World Health Organization. Antibiotic resistance. 2020-07-31, cited 2022-05-14. 2022-05-14. Available from URL: https://www.who.int/news-room/fact-sheets/detail/antibiotic-resistance.
9. Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis 2016; 63: e61-111.
10. Martin-Loeches I, Torres A, Rinaudo M, et al. Resistance patterns and outcomes in intensive care unit (ICU)-acquired pneumonia. Validation of European Centre for Disease Prevention and Control (ECDC) and the Centers for Disease Control and Prevention (CDC) classification of multidrug resistant organisms. J Infect 2015; 70: 213-22.
11. Yang WQ, Zhao ZX, Xu Y, Liu J, Xue JX, Guan SL. Advances in the use of constituents of Traditional Chinese Medicines to inhibit multidrug-resistant bacteria. Zhong Guo Bing Yuan Sheng Wu Xue Za Zhi 2021; 16: 734-7.
12. Su T, Qiu Y, Hua XS, et al. Novel opportunity to reverse antibiotic resistance: to explore Traditional Chinese Medicine with potential activity against antibiotics-resistance bacteria. Front Microbiol 2020; 11: 610070.
13. Yin YY, Yue ZD, Ding Y, Yu SH. Study on the mechanism of Buzhong Yiqi decoction on the recovery period of COVID-19 based on network pharmacology. Shandong Zhong Yi Yao Da Xue Xue Bao 2021; 45: 685-94.
14. An HM. Efficiency of Traditional Chinese Medicine modified Buzhong Yiqi decoction on the prognosis of patients with ventilator-associated pneumonia. Zhong Xi Yi Jie He Xin Xue Guan Bing Dian Zi Za Zhi 2020; 8: 171.
15. Kou LJ, Liu QQ, Jiang QM, et al. Clinical study on the effect of modified Buzhong Yiqi decoction on the prognosis of patients with ventilator-associated pneumonia. Zhong Guo Zhong Yi Ji Zheng 2011; 20: 202+208.
16. Peng MH, Chen XB, Ruan XM, Zhang T. Curative effect of Buzhong Yiqi decoction in the treatment of multidrug-resistant pneumonia after stroke. Shi Yong Zhong Yi Yao Za Zhi 2019; 35: 1457-8.
17. Kohno J, Kawamura T, Kikuchi A, Akaishi T, Takayama S, Ishii T. A Japanese traditional medicine Hochuekkito promotes negative conversion of vancomycin-resistant Enterococci. Sci Rep 2021; 11: 11300.
18. Deng D, Chen ZY, Jia LY, et al. Treatment of hospital-acquired pneumonia with multi-drug resistant organism by Buzhong Yiqi decoction based on Fuzheng Quxie classical prescription: study protocol for a randomized controlled trial. Trials 2019; 20: 817.
19. Infections Group, Chinese Society of Respiratory, Chinese Medical Association. Guidelines for the diagnosis and treatment of hospital-acquired pneumonia and ventilator-associated pneumonia in Chinese adults (2018 edition). Zhong Hua Jie He He Hu Xi Za Zhi 2018; 41: 255-80.
20. Lyu HH. Clinical study on Buzhong Yiqi decoction combined with Western Medicine in treating stroke-associated pneumonia. Zhong Guo Zhong Yi Yao Xian Dai Yuan Cheng Jiao Yu 2018, 16: 115-7.
21. Gulick AM. Nonribosomal peptide synthetase biosynthetic clusters of ESKAPE pathogens. Nat Prod Rep 2017; 34: 981-1009.
22. Yin Y, Zhao C, Li H, et al. Clinical and microbiological characteristics of adults with hospital-acquired pneumonia: a 10-year prospective observational study in China. Eur J Clin Microbiol Infect Dis 2021; 40: 683-90.
23. Martin-Loeches I, Rodriguez AH, Torres A. New guidelines for hospital-acquired pneumonia/ventilator-associated pneumonia: USA vs Europe. Curr Opin Crit Care 2018; 24: 347-52.
24. Chen G, Xu KL, Sun FY, Sun YX, Kong ZY, Fang BJ. Risk factors of multidrug-resistant bacteria in lower respiratory tract infections: a systematic review and Meta-analysis. Can J Infect Dis Med Microbiol 2020; 2020: 7268519.
25. Torres A, Ewig S, Lode H, Carlet J. Defining, treating and preventing hospital acquired pneumonia: European perspective. Intensive Care Med 2009; 35: 9-29.
26. Wetzel C, Lonneman M, Wu C. Polypharmacological drug actions of recently FDA approved antibiotics. Eur J Med Chem 2021; 209: 112931.
27. Brown DG, Wobst HJ. A decade of FDA-approved drugs (2010-2019): trends and future directions. J Med Chem 2021; 64: 2312-38.
28. Khaksarian M, Bahmani M, Taherikalani M, Ashrafi B, Rafieian-Kopaei M, Abbasi N. Biosynthesis of titanium dioxide nanoparticles using Hypericum perforatum and Origanum vulgare extracts and their main components, hypericin and carvacrol as promising antibacterial agents. J Tradit Chin Med 2022; 42: 167-75.
29. Cai Y, Zhang Q, Fu Y, et al. Effectiveness of Chinese herbal medicine combined with antibiotics for extensively drug-resistant enterobacteria and nonfermentative bacteria infection: real-life experience in a retrospective cohort. Biomed Res Int 2017; 2017: 2897045.
30. Yamada T, Wajima T, Nakaminami H, Kobayashi K, Ikoshi H, Noguchi N. The modified Gingyo-san, a Chinese herbal medicine, has direct antibacterial effects against respiratory pathogens. BMC Complement Altern Med 2016; 16: 463.
31. Wei Q, Bhasme P, Wang Z, et al. Chinese medicinal herb extract inhibits PQS-mediated quorum sensing system in Pseudomonas aeruginosa. BMC Complement Altern Med 2020; 248: 112272.
32. Hou Y, Nie Y, Cheng B, et al. Qingfei Xiaoyan Wan, a Traditional Chinese Medicine formula, ameliorates Pseudomonas aeruginosa-induced acute lung inflammation by regulation of PI3K/AKT and Ras/MAPK pathways. Acta pharmaceutica Sinica B 2016; 6: 212-21.
33. Baillie JK, Digard P. Influenza--time to target the host? N Engl J Med 2013; 369: 191-3.
34. Takayama S, Kikuchi A, Makino T, Kainuma M, Namiki T, Ito T. Basic pharmacological mechanisms and clinical evidence of the efficacy of hochuekkito against infectious diseases and its potential for use against COVID-19. Trad Kampo Med 2021; 8: 3-21.
Options
Outlines

/

〈 〉